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Antithymocyte globulins (ATG) such as rabbit ATG (Thymo-
globulin) are immunosuppressive agents known to deplete T cells,
and there is increasing evidence that they may also affect T cell
migration. In this study, we sought to determine if Thymoglobulin
affects L-selectin-dependent lymphocyte binding to lymph node
high endothelial venules (HEV), the ﬁrst step in migration of
lymphocytes to lymph nodes. Human peripheral blood lympho-
cytes were collected by Ficoll centrifugation of citrated blood and
T cells were isolated by magnetic bead separation. T cells were
exposed to Thymoglobulin at 10, 20, 30, 40, and 50 ug/ml for 30
minutes at 4° C; controls consisted of puriﬁed rabbit immunoglob-
ulin at identical concentrations. The capacity of T cells to engage
HEV was measured by Stamper-Woodruff assay. Additionally,
parallel plate ﬂow chamber studies were performed under physio-
logic shear stress conditions to measure T cell binding to L-
selectin ligands expressed on the hematopoietic cell line, KG1a.
Incubation of T cells with Thymoglobulin led to a dose-dependent
decrease in binding to HEV, with complete abrogation at 50
ug/ml. Similarly, Thymoglobulin blunted L-selectin-mediated
binding interactions in parallel plate ﬂow studies. Flow cytometry,
performed using a variety of anti-L-selectin mAb showed, ironi-
cally, that incubation of T cells with Thymoglobulin resulted in an
increase in the percent marker cells and the mean channel ﬂuo-
rescence for L-selectin epitopes targeted by mAbs TQ-1 and
LAM1-116, with no change in the levels of the DREG56 epitope.
These changes were speciﬁc for L-selectin, as there were no
changes in expression of VLA-4 using the same conditions. Im-
portantly, as shown by analysis of Thymoglobulin immunoprecipi-
tates of biotinylated T cells, Thymoglobulin does not directly
recognize L-selectin. These ﬁndings indicate that the effects of
Thymoglobulin on L-selectin function are not related to decreased
surface expression, but appear to be related to changes in L-
selectin topography affecting L-selectin’s capacity to engage its
ligand(s). Further studies are in progress to deﬁne the nature of
these changes and how modulation of L-selectin topography is
achieved by Thymoglobulin. Operationally, changes in L-selectin
function could have profound implications in the ability of circu-
lating lymphocytes to enter lymphoid tissues, inhibiting appropri-
ate antigen-recognition and subsequent generation of immune
responses.
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APOPTOTIC DONOR LEUKOCYTES INHIBIT TOLERANCE AND LIMIT
MIXED CHIMERISM INDUCED BY CD40-CD154 BLOCKADE IN ALLOGE-
NEIC BONE MARROW TRANSPLANTATION
Li, J.-M.1, Giver, C.R.1, Gorechlad, J.1, Larsen, C.P.2, Waller, E.K.1
1. Winship Cancer Institute, Emory University, Atlanta, GA; 2. The
Carlos and Marguerite Mason Transplantation Research Center, De-
partment of Surgery, Emory University, Atlanta, GA.
Background: “Mini” transplants using non-myeloablative con-
ditioning can avoid early post-transplant toxicity associated with
myeloablative conditioning prior to allogeneic hematopoietic pro-
genitor cell transplantation (HPCT), but graft-versus-host-disease
(GvHD) and graft rejection remain clinical problems. We previ-
ously found that low-dose busulfan conditioning and costimulatory
blockade using anti-CD154 monoclonal antibody (mAb) were suf-
ﬁcient to establish stable mixed chimerism without GvHD when
transplanting moderate doses of T cell depleted bone marrow
(TCD-BM) from MHC fully mismatched donors (Adams et al,
J Immunol 167:1103, 2001). Additionally, several groups have
shown that apoptotic cells can contribute to immune tolerance in
HPCT. Therefore, in an effort to enhance donor chimerism and
graft-versus-leukemia activity, we evaluated the ability of different
preparations of donor lymphocytes to provide a tolerizing effect
and facilitate stable donor chimerism when administered prior to
the BM graft. Methods: In B63B10BR and BALB/c3B6 MHC
fully mismatched transplant pairs, donor lymphocytes were treated
ex-vivo with different immunosuppressive regimens (ﬂudarabine,
psoralen-UVA, -irradiation) and used as tolerizing DLI 6 days
prior to HPCT, co-administered with anti-CD154 mAb and low-
dose busulfan conditioning. We also compared the use of donor
lymphocytes that had been enriched for, or depleted of, T cells or
CD11b/CD11b subsets as tolerizing DLI in the same “mini”-
transplant setting. Results: Long-term mixed-chimerism without
GvHD was enhanced by pre-transplant administration of viable
allogeneic splenocytes (Table 1). Unexpectedly, the use of apopto-
tic/necrotic donor splenocytes resulted in diminished donor en-
graftment. Puriﬁed splenic T cells more potently enhanced donor
chimerism compared to unfractionated splenocytes, T cell de-
pleted splenocytes, or the CD11b and CD11b fractions of
donor splenocytes. In a leukemia model, the survival of recipients
with mixed-chimerism following low-dose busulfan and co-stimu-
latory blockade was enhanced by viable post-transplant donor T
cell infusions. Conclusions: Host tolerance of donor cells follow-
ing non-myeloablative conditioning and co-stimulatory blockade is
an active process enhanced by viable donor immune cells. The
diminished donor chimerism obtained with apoptotic/necrotic do-
nor splenocytes suggests that dying cells interfere with the donor-
speciﬁc tolerance generated by anti-CD154 mAb.
Conditioning and Transplantation (B63B10BR)
Donor Chimerism (%)
(no. engraftment
[donor cells >1%] mice/
all mice in the group)
Tolerizing DLI
(3107) i.v. at d-6
	CD154
mAb (i.v. at
d-7, 6,
4, 2, 0,
& 6)
Busulfan
(i.p at d-1)
TCD-BM
(i.v at d0) d  30 d  60 d  160
No Tolerizing DLI no 20 mg/kg 2107 0 0 0
No Tolerizing DLI 500g 20 mg/kg 2107 42 10 35 21 44 20
Un-manipulated SP 500g 20 mg/kg 2107 65 7* 52 17* 79 7*
CD3() SP 500g 20 mg/kg 2107 ND 68 6* ND
CD11b() SP 500g 20 mg/kg 2107 ND 43 4 ND
Fludarabine
treated-SP
500g 20 mg/kg 2107 45 6 ND 52 4
PUVA treated-SP 500g 20 mg/kg 2107 33 13 ND 47 23
Irradiated-SP (7.5 Gy) 500g 20 mg/kg 2107 28 24* ND 42 22
Irradiated-SP (15 Gy) 500g 20 mg/kg 2107 12 15* ND 20 17*
Irradiated-SP (30 Gy) 500g 20 mg/kg 2107 2 4*
(5/10) no.
ND 4 7*
(4/10) no.
*P .05 vs recipients of No Tolerizing DLI with 
CD154 mAb at
same time point.
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RAPID IMMUNE RECONSTITUTION AND COMPLETE DONOR CHIMER-
ISM AFTER NON-MYELOABLATIVE ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION (NMSCT) IN PEDIATRIC PATIENTS
(PTS) WITH MALIGNANCY
Fry, T.J.1, Rager, A.1,2, Hakim, F.3, Love, C.1, Layton, P.1,
Fowler, D.3, Bishop, M.R.3, Gress, R.3, Mackall, C.L.1, Wayne, A.S.1 1.
Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD; 2. Duke
University School of Medicine, Durham, NC; 3. Experimental Trans-
plantation and Immunology Branch, CCR, NCI, NIH, Bethesda, MD.
Background: Experience with NMSCT for pediatric cancer is
limited. Compared to adults, children and adolescents have less
immune depletion and improved reconstitution after chemother-
apy, which might increase the risk of graft rejection or mixed
chimerism. On the other hand, preserved host thymic function
might enhance donor-derived immune recovery. We postulated
that pre-transplant immune depletion followed by T cell replete
NMSCT would facilitate donor engraftment and enhance post-
transplant immune reconstitution. Methods: We piloted a novel
regimen in 21 pediatric pts (median age 14, range 4–21) with
high-risk hematologic malignancies and sarcomas. Fludarabine-
based induction chemotherapy was administered for disease con-
trol and targeted CD4 count reduction. Pre-transplant condition-
ing consisted of cyclophosphamide (1200 mg/m2/day) and
ﬂudarabine (30 mg/m2/day)  4 days plus melphalan (100 mg/m2
 1 dose in sarcoma pts). Grafts consisted of G-CSF mobilized
unmodiﬁed peripheral blood stem cells from 5-6/6 HLA-matched
ﬁrst-degree relatives (median CD34 dose 11.7  106/kg, range
4.4–19.1; median CD3 dose 416  106/kg, range 228–815). Cy-
closporine was used for GVHD prophylaxis. Results: Induction
therapy dramatically reduced CD4 counts. Donor-derived engraft-
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ment was rapid. Median time to achieve an absolute neutrophil
count 	500 cells/L was post-transplant day (D) 9 (range,
8–11). Full donor lymphoid chimerism (95% by VNTR-PCR on
CD3 sorted peripheral blood) was achieved in all pts (18/21 D 
14; 21/21 D  28). Immune recovery was brisk and sustained.
CD4, CD8, and NK cell numbers exceeded those at study entry by
D  28. Serum IL-7 levels were inversely correlated with CD4
counts. B-cell counts approached entry values by D  100. Sub-
stantial numbers of naive (CD45RA/CD62L) CD4 and
CD8 T cells were detected on D  28, suggestive of early
recovery of thymic function. Conclusions: Targeted pre-trans-
plant immune depletion and NMSCT results in rapid, sustained
donor-derived engraftment and immune reconstitution in pediatric
pts with malignancy. Early immune recovery includes naive T cell
subsets and B cells. Despite potential obstacles in pediatric pts,
NMSCT conditioning can induce rapid engraftment and immue
reconstitution, which may allow application of this novel platform
to direct allogeneic anti-tumor immune responses in high-risk
childhood cancers (Table 1).
Table 1. Immune Depletion and Recovery (Mean Cell Counts/L)
Pre Post D  0 D  28 D  60 D  100 D  180
CD4 304 156 27 394 376 313 413
CD8 344 226 4 561 684 635 544
Naive CD4 69 35 20 123 64 100 118
Naive CD8 130 49 87 192 137 206 169
B cell 115 3 4 12 94 106 200
NK cell 87 111 1 274 222 154 130
Data represent mean cell counts/L; Pre: entry; Post: after induc-
tion; D: post-transplant day.
231
PERIPHERAL T CELL APOPTOSIS AFFECTS IMMUNE RECONSTITUTION
AFTER ALLOGENEIC BMT
Alpdogan, O.1, McGoldrick, S.1, Lu, S.1, Patel, N.1, Suh, D.1,
Smith, O.M.1, van den Brink, M.R.M.1 Memorial Sloan-Kettering
Cancer Center, New York, NY.
Post-transplant T cell deﬁciency (especially in adults) is related to
impaired thymus-dependent lymphopoiesis. However, others and
we have previously found in human and murine studies that pe-
ripheral T cell apoptosis is increased in recipients of an allogeneic
bone marrow transplantation (allo BMT). We used murine BMT
models to further analyze peripheral T cell apoptosis in recipients
of a T cell-depleted (TCD) or T cell-replete BMT. In recipients of
a TCD BMT, we found that donor derived T cells had a high
percentage of apoptotic cells (Annexin-V) in both syngeneic and
allogeneic hosts when analyzed at days 14 and 28 after BMT.
Cleaved caspase-3 levels in these T cells were also increased in
comparison with non-transplanted controls. Both CD4 and
CD8 memory (CD44hi) T cells had a higher percentage of
apoptotic cells compared to naive (CD44lo) cells. This was asso-
ciated with decreased levels of intracellular Bcl-2 in de novo gen-
erated T cells from both young and old recipients of an allo
TCD-BMT. We then transplanted allogeneic hosts with bone
marrow (BM) from RAG-2-eGFP transgenic mice to examine
apoptosis in newly generated T cells (recent thymic emigrants
[RTE]) and found increased apoptotic cells in both eGFPhi and
eGFPlo T cells. This demonstrates that both non-divided (eGF-
Phi) and proliferating (eGFPlo) donor BM derived T cells can
undergo apoptosis in the periphery after TCD-BMT. In recipients
with GVHD, we observed a severe loss of thymic cellularity and
low numbers of BM derived de novo generated T cells with a high
fraction of apoptotic cells. These had very low Bcl-2 expression and
increased caspase 8 and 9 activation. Conversely, alloreactive T
cells (from the mature donor T cells in the allograft) showed
upregulation of Fas expression, higher Bcl-2 levels, less caspase
activity, and contained lower numbers of apoptotic T cells com-
pared to BM derived T cells. Allogeneic recipients receiving donor
BM deﬁcient for Fas, Fas Ligand and TRAIL, or over-expressing
Bcl-2 and Akt had no decrease in donor derived apoptotic T cells,
suggesting that these molecules were not absolutely required for
post-transplant peripheral T cell apoptosis. We conclude that
newly generated donor BM derived T cells have increased periph-
eral T cell apoptosis, especially in older recipients and in recipients
with GVHD, which could be an important factor in the delay of
post-transplant T cell reconstitution.
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IMMUNE RECONSTITUTION AFTER CD8-DEPLETED OR UNMANIPU-
LATED PERIPHERAL BLOOD STEM CELLS TRANSPLANTATION FOL-
LOWING NONMYELOABLATIVE CONDITIONING: RESULTS FROM A
PROSPECTIVE RANDOMIZED TRIAL
Castermans, E.1, Baron, F.1, Willems, E.1, Meuris, N.1,
Schaaf-Lafontaine, N.1, Cheynier, R.2, Geenen, V.1, Sekaly, R.-P.3,
Beguin, Y.1 1. CHU de Liege, Liege, Belgium; 2. Institut Pasteur, Paris,
France; 3. Centre de Recherches du CHUM, Hotel-Dieu, Montreal, QC,
Canada.
Aim of the study: We assessed the impact of CD8-depletion
(performed in an effort to reduce the incidence of acute GVHD)
on immune reconstitution after peripheral blood stem cell trans-
plantation (PBSCT) with nonmyeloablative conditioning consist-
ing of 2 Gy TBI with (n  39) or without (n  11) ﬂudarabine.
Patients and methods: 50 patients were randomised between
CD8-depletion (n  22) and lack of any manipulation (n  28).
Median patient age was 57 (range 36–69) years. Twenty patients
received grafts from HLA-matched related donors and 30 from
unrelated donors. CD8-depletion was performed with the Eligix
system. GvHD prophylaxis consisted of mycophenomate mofetil
(MMF) and cyclosporine (CSP). The different peripheral blood
subpopulations were analyzed by 3-color ﬂow-cytometry on days
28, 40, 60, 80, 100, 120, 180, and 365 after PBSCT. The diversity
of the Vb repertoire in CD4 and CD8 T cells was assessed by
rt-PCR on day 180 after PBSCT. Thymic output was determined
through analyses of sjTRECS by quantitative PCR on days 100 and
365 after PBSCT. The expression of transcription factor Foxp3
was measured by quantitative RT-PCR on days 100 and 365 after
PBSCT in order to assess regulatory T cells population. The
impact of PBSC manipulation on T cell subsets recovery was
analyzed by the Mann-Whitney rank sum test. Results: The me-
dian number of CD34, CD3, CD4, and CD8 cells 
106/kg infused were 4.1, 315, 185, and 131 in the unmanipulated
group versus 3.7 (NS), 110 (P  .001), 94 (P  .002), and 4 (P 
.001) in the CD8-depleted group, respectively.CD8 depletion sig-
niﬁcantly impaired recovery of CD3CD8 T cells on days 100,
120, and 180 after HCT (P  .02, P  .02 and P  .03, respec-
tively), but not those of CD3 T cells, CD3CD4 T cells,
CD45RA T cells, CD19B-cells, or CD56NK cells. CD3T
cell chimerism levels from day 28 to day 80 were also signiﬁcantly
decreased in the CD8-depleted group. The levels of sjTRECS
after HCT correlated with those of CD3CD4CD45RA T
cells (Spearman R  0.41, P  .0034).The diversity of VB reper-
toire among CD4 and CD8 T cells on day 180 was similar
among the 2 groups, as were the sjTRECS and Foxp3 levels.
Conclusions: CD8-depletion of PBSC decreased T cell chimer-
ism levels and recovery of CD8 T cells, but did not affect
recovery of other cell subsets, thymic output, nor Vb repertoire
diversity, suggesting that immune reconstitution the ﬁrst year after
HCT was mainly driven by expansion of mature T cells contained
in the graft.
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OPTIMIZATION OF EXPANSION OF CORD BLOOD T CELLS WITH ANTI-
CD3/ANTI-CD28 COATED BEADS
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